KDMN Kadmon Holdings Inc.

3.99
-0.14  -3%
Previous Close 4.13
Open 4.16
Price To Book 5.18
Market Cap 517,466,635
Shares 129,690,886
Volume 1,557,054
Short Ratio 12.04
Av. Daily Volume 1,328,225
Stock charts supplied by TradingView

NewsSee all news

  1. Kadmon Announces Closing of $101.6mm Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of common stock for gross

  2. Kadmon to Participate in Upcoming Investor Conferences

    NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following investor

  3. Kadmon Announces Pricing of Public Offering of Common Stock

    NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) ("Kadmon") today announced the pricing of an offering of 26,000,000 shares of its common stock at a public offering price of

  4. Kadmon Announces Proposed Public Offering of Common Stock

    NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) ("Kadmon") today announced its intention to offer and sell shares of its common stock in a public offering pursuant to its

  5. Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease

    KD025 Achieved ORRs of 64% with KD025 200 mg QD and 67% with KD025 200 mg BID Conference Call Today at 5:00 p.m. Eastern TimeNEW YORK / ACCESSWIRE / November 11, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial enrolling as of November 2017.
Tesevatinib
Autosomal dominant Polycystic Kidney Disease (ADPKD)
Phase 2 trial met primary endpoint - November 11, 2019. Primary analysis due 1Q 2020.
KD025 - ROCKstar (KD025-213)
Chronic graft-versus-host disease (cGVHD)
Phase 2 data released February 12, 2018. Open label - noted data were "positive".
KD025
Idiopathic pulmonary fibrosis (IPF)
Phase 2 first patient dosed September 2016, approximately 50% enrolled as of August 2017.
KD025
Moderate to severe chronic plaque psoriasis
Phase 2 initiated August 2016. Enrollment ongoing as of May 15, 2017.
Tesevatinib
Recurrent glioblastoma - cancer
Phase 2 trial initiation announced July 9, 2019.
KD025
Systemic sclerosis (scleroderma)
Phase 1 trial to be initiated 2H 2019.
KD045
Fibrosis (kidney/lung/liver)
Phase 2 data due to be presented at ASH December 2019.
KD025-208
Chronic graft-versus-host disease (cGVHD)

Latest News

  1. Kadmon Announces Closing of $101.6mm Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of common stock for gross

  2. Kadmon to Participate in Upcoming Investor Conferences

    NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following investor

  3. Kadmon Announces Pricing of Public Offering of Common Stock

    NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) ("Kadmon") today announced the pricing of an offering of 26,000,000 shares of its common stock at a public offering price of

  4. Kadmon Announces Proposed Public Offering of Common Stock

    NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) ("Kadmon") today announced its intention to offer and sell shares of its common stock in a public offering pursuant to its

  5. Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease

    KD025 Achieved ORRs of 64% with KD025 200 mg QD and 67% with KD025 200 mg BID Conference Call Today at 5:00 p.m. Eastern TimeNEW YORK / ACCESSWIRE / November 11, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced

  6. Kadmon Establishes Strategic Partnership with BioNova to Develop and Commercialize KD025 for the Treatment of GVHD in China

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively develop and

  7. Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2019."Following the

  8. Kadmon Announces Sale of 1.4 Million Shares of MeiraGTx Holdings plc

    NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the Company has entered into a transaction to divest approximately 1.4 million shares of MeiraGTx Holdings plc stock

  9. Kadmon to Participate in Upcoming Investor Conferences

    NEW YORK, NY / ACCESSWIRE / September 23, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will participate in the following investor

  10. Kadmon to Participate in Upcoming Investor Conferences

    NEW YORK, NY / ACCESSWIRE / September 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will participate in the following investor conferences